Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but ...

A former college athlete, 51-year-old Charles never thought he'd have to worry about his weight. But football injuries and a ...

Zepbound led to an average weight loss of 20.2 percent compared to Wegovy's 13.7 percent. We talked with healthcare experts to understand the study’s findings, what sets these drugs apart and ...

Wegovy, like Zepbound, is FDA-approved for weight loss. Its main ingredient is semaglutide, which is also found in Ozempic, a medication that is approved by the FDA to treat Type 2 diabetes but is ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.

Zepbound, a weight loss drug by Eli Lily, received FDA approval. How the tirzepatide-containing drug works, potential side effects, and insurance coverage.

Zepbound is approved for weight loss and management, while Mounjaro is approved for the treatment of Type 2 diabetes. — Comorbidities. Mounjaro is approved for those with Type 2 diabetes.

Doctors and many patients say GLP-1 drugs can help solve the growing problem of obesity. But some bristle at the thought that ...

Novo Nordisk's weight-loss medication, Wegovy, uses semaglutide, which only focuses on GLP-1. That difference translated to greater weight loss with Zepbound than Wegovy, a recent study found.

How much does the weight loss drug Zepbound cost? Eli Lilly is expanding its supply of Zepbound, a weight loss drug with tirzepatide as its active ingredient. On August 27, the company announced ...